These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [In vitro combination effect of pazufloxacin with various antibiotics against Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus]. Maekawa M; Takahashi K; Takahata M; Minami S Jpn J Antibiot; 2002 Aug; 55(4):440-5. PubMed ID: 12378872 [TBL] [Abstract][Full Text] [Related]
3. [Combination effect of arbekacin and cefepime on mixed culture of MRSA and P. aeruginosa]. Araake M; Hara T; Miyata A; Tani M; Ogawa H Jpn J Antibiot; 2001 Feb; 54(2):69-78. PubMed ID: 11338680 [TBL] [Abstract][Full Text] [Related]
4. [Bacteriological evaluations of combination effects with cefotiam and other antimicrobial agents against methicillin-resistant Staphylococcus aureus. II. Synergistic actions of cefotiam with arbekacin and minocycline]. Deguchi K; Yokota N; Koguchi M; Suzuki Y; Suzuki K; Fukayama S; Ishihara R Jpn J Antibiot; 1993 Feb; 46(2):123-9. PubMed ID: 8331772 [TBL] [Abstract][Full Text] [Related]
5. [Combined effect of vancomycin or teicoplanin plus a beta-lactam antibiotic in mouse infection models caused by beta-lactam antibiotec-induced vancomycin resistant MRSA (BIVR)]. Hatano K; Yokota Y; Hanaki H; Sunakawa K Kansenshogaku Zasshi; 2006 May; 80(3):243-50. PubMed ID: 16780131 [TBL] [Abstract][Full Text] [Related]
6. [Evaluation of the activity and effects of combinations of various antibacterial agents against methicillin-resistant Staphylococcus aureus in vitro]. Kouda M; Homma S; Udagawa I; Fukuhara J; Takeuchi M; Tamura K Jpn J Antibiot; 2000 Mar; 53(3):171-8. PubMed ID: 10834148 [TBL] [Abstract][Full Text] [Related]
7. [Reliability of disc-diffusion susceptibility testing for arbekacin, vancomycin and teicoplanin against methicillin-resistant Staphylococcus aureus]. Kouda M; Homma S; Udagawa I; Tamura K; Fukuhara J; Takeuchi M Jpn J Antibiot; 1999 Dec; 52(12):681-9. PubMed ID: 10695023 [TBL] [Abstract][Full Text] [Related]
8. Characterization of beta-lactam antibiotic-induced vancomycin-resistant MRSA (BIVR) in a patient with septicemia during long-term vancomycin administration. Yamaguchi Y; Hanaki H; Yanagisawa C; Ikeda-Dantsuji Y; Hashimoto T; Yazaki H; Sugahara K; Yanagisawa T; Kawajiri H; Sato S; Ishizaki A; Tachihara-Sato R; Takahashi Y; Ono T; Kageyama Y; Kawaguchi T; Tamura A; Hagane K; Sunakawa K J Infect Chemother; 2009 Oct; 15(5):274-8. PubMed ID: 19856063 [TBL] [Abstract][Full Text] [Related]
9. [Antibacterial activities of arbekacin against recently isolated methicillin-resistant Staphylococcus aureus (I)]. Deguchi K; Yokota N; Koguchi M; Suzuki Y; Suzuki K; Fukayama S; Ishihara R Jpn J Antibiot; 1993 Mar; 46(3):234-41. PubMed ID: 8510320 [TBL] [Abstract][Full Text] [Related]
10. The antagonistic effects of a combination of vancomycin and minocycline in Staphylococcus aureus with heterogeneous resistance to vancomycin. Oshiro T; Nagasawa Z; Hanaki H; Ikeda-Dantsuji Y; Nagayama A J Infect Chemother; 2008 Feb; 14(1):15-22. PubMed ID: 18297444 [TBL] [Abstract][Full Text] [Related]
11. [Attenuation of arbekacin-induced nephrotoxicity in rats by pazufloxacin mesilate]. Kizawa K; Miyazaki M; Nagasawa M; Ogake N; Nagai A; Sanzen T; Kawamura Y Jpn J Antibiot; 2003 Feb; 56(1):44-54. PubMed ID: 12723398 [TBL] [Abstract][Full Text] [Related]
12. [Treatment with arbekacin of surgical infections by resistant strains of Staphylococcus aureus. Arbekacin Study Group]. Morimoto K; Nakatani S; Kaji M; Kinoshita H; Fujimoto M; Hirata S; Ueda T; Tamate S; Yamazaki O Jpn J Antibiot; 1994 Jun; 47(6):826-36. PubMed ID: 8072193 [TBL] [Abstract][Full Text] [Related]
13. [Effect of arbekacin on the production of toxic shock syndrome toxin 1 by methicillin-resistant Staphylococcus aureus]. Miyata A; Araake M; Ogawa H; Hanaki H; Hiramatsu K Jpn J Antibiot; 2001 Jul; 54(7):372-81. PubMed ID: 11560056 [TBL] [Abstract][Full Text] [Related]
14. [Basic studies on combination effects of arbekacin and beta-lactam antibiotics on methicillin-resistant Staphylococcus aureus]. Watanabe T; Sobu K; Takase Y; Kawabata T; Kanno M; Yoshida T Jpn J Antibiot; 1994 Jun; 47(6):701-9. PubMed ID: 8072178 [TBL] [Abstract][Full Text] [Related]
15. [Antibacteriological activities of arbekacin and vancomycin against strains of MRSA]. Ishii T; Takayama Y; Takase Y; Orikasa Y Jpn J Antibiot; 1994 Jun; 47(6):647-54. PubMed ID: 8072173 [TBL] [Abstract][Full Text] [Related]
16. [Evaluation of rapid antimicrobial susceptibility test for Staphylococcus aureus by chemiluminescent assay and its application for screening of beta-lactam antibiotic induced vancomycin-resistant MRSA]. Nagasawa Z; Nakashima Y; Oho M; Kusaba K; Manome I; Nagayama A Rinsho Biseibutshu Jinsoku Shindan Kenkyukai Shi; 2008; 19(1-2):7-15. PubMed ID: 19583457 [TBL] [Abstract][Full Text] [Related]
17. [Combination effect of teicoplanin and various antibiotics against hetero-VRSA and VRSA]. Hanaki H; Hiramatsu K Kansenshogaku Zasshi; 1999 Oct; 73(10):1048-53. PubMed ID: 10565121 [TBL] [Abstract][Full Text] [Related]
18. [Vancomycin and arbekacin, drugs of treatment for MRSA infections]. Kobayashi Y Nihon Rinsho; 1992 May; 50(5):1054-9. PubMed ID: 1507428 [TBL] [Abstract][Full Text] [Related]
19. In vitro combined effects of cefozopran/teicoplanin and cefozopran/vancomycin on methicillin-resistant Staphylococcus aureus. Toyokawa M; Asari S; Nishi I; Horikawa M; Tsukamoto H; Sunada A; Ueda A; Iwatani Y J Chemother; 2003 Feb; 15(1):31-6. PubMed ID: 12678411 [TBL] [Abstract][Full Text] [Related]